在持续鲁索替尼治疗基础上加用纳维托克治疗进展或反应欠佳的骨髓纤维化患者:II期安全性与疗效
这项II期试验在34例对稳定剂量鲁索替尼(≥10 mg每日两次)治疗进展或反应欠佳的中危/高危骨髓纤维化成人患者中,加用BCL-XL/BCL-2抑制剂纳维托克(起始50 mg每日一次,血小板≥75×10^9/L时递增至最大300 mg每日一次)。第24周脾体积缩小≥35%(SVR35)率为26.5%,研究期间任意时间达41%,估计中位SVR35持续13.8个月;第24周总症状评分降低≥50%(TSS50)率为30%(6/20),33%(11/33)可评估患者骨髓纤维化分级改善1-2级,贫血缓解率64%(7/11),中位随访21.6个月中位总生存未达到。
要点
- 纳维托克联合鲁索替尼在第24周SVR35率为26.5%,任意时间达41%,估计中位持续13.8个月。
- 第24周TSS50率为30%(6/20),33%(11/33)可评估患者骨髓纤维化分级改善1-2级。
- 贫血缓解率64%(7/11),最常见不良事件为可逆性血小板减少(88%)且无临床显著出血。
核心结论
- 在持续或进展性骨髓纤维化患者中,鲁索替尼加用纳维托克可产生持久的SVR35,并改善总症状评分、血红蛋白缓解和骨髓纤维化。
- 原文指出正在进一步研究以验证其疾病修饰潜力。
研究设计与样本
- II期试验(ClinicalTrials.gov标识:NCT03222609),纳入34例中危/高危骨髓纤维化成人患者,这些患者在稳定鲁索替尼剂量(≥10 mg每日两次)下出现进展或反应欠佳。
- 纳维托克起始剂量为50 mg每日一次,随后每周递增一次,在血小板≥75×10^9/L时递增至最大300 mg每日一次。
- 主要终点为第24周脾体积较基线缩小≥35%(SVR35);次要终点包括第24周总症状评分较基线降低≥50%(TSS50)、血红蛋白改善、骨髓纤维化分级变化和安全性。
主要发现
- 58%的患者检出高分子的风险突变,52%携带≥3个突变。
- 第24周SVR35率为26.5%,研究期间任意时间达41%,估计中位SVR35持续13.8个月。
- 第24周TSS50率为30%(6/20),33%(11/33)可评估患者骨髓纤维化分级改善1-2级。
- 贫血缓解率为64%(7/11),包括1例基线输血依赖患者。
- 中位随访21.6个月,中位总生存未达到;最常见不良事件为可逆性血小板减少且无临床显著出血(88%)。
关键数值与推荐
- SVR35定义为脾体积较基线缩小≥35%;第24周SVR35率为26.5%,任意时间SVR35率为41%,估计中位SVR35持续13.8个月。
- TSS50定义为总症状评分较基线降低≥50%;第24周TSS50率为30%(6/20)。
- 骨髓纤维化分级改善1-2级见于33%(11/33)可评估患者;贫血缓解率为64%(7/11)。
- 入组要求鲁索替尼稳定剂量≥10 mg每日两次;纳维托克起始50 mg每日一次,血小板≥75×10^9/L时递增至最大300 mg每日一次。
临床怎么用
- 原文未据此给出推荐。
- 作者指出正在进一步研究以验证纳维托克联合鲁索替尼的疾病修饰潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Targeting the BCL-XL pathway has demonstrated the ability to overcome Janus kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy and safety of adding BCL-XL/BCL-2 inhibitor navitoclax to ruxolitinib therapy in patients with myelofibrosis with progression or suboptimal response to ruxolitinib monotherapy (ClinicalTrials.gov identifier: NCT03222609). METHODS: Thirty-four adult patients with intermediate-/high-risk myelofibrosis who had progression or suboptimal response on stable ruxolitinib dose (≥ 10 mg twice daily) were administered navitoclax at 50 mg once daily starting dose, followed by escalation to a maximum of 300 mg once daily in once in weekly increments (if platelets were ≥ 75 × 109/L). The primary end point was ≥ 35% spleen volume reduction (SVR35) from baseline at week 24. Secondary end points included ≥ 50% reduction in total symptom score (TSS50) from baseline at week 24, hemoglobin improvement, change in bone marrow fibrosis (BMF) grade, and safety. RESULTS: High molecular risk mutations were identified in 58% of patients, and 52% harbored ≥ 3 mutations. SVR35 was achieved by 26.5% of patients at week 24, and by 41%, at any time on study, with an estimated median duration of SVR35 of 13.8 months. TSS50 was achieved by 30% (6 of 20) of patients at week 24, and BMF improved by 1-2 grades in 33% (11 of 33) of evaluable patients. Anemia response was achieved by 64% (7 of 11), including one patient with baseline transfusion dependence. Median overall survival was not reached with a median follow-up of 21.6 months. The most common adverse event was reversible thrombocytopenia without clinically significant bleeding (88%). CONCLUSION: The addition of navitoclax to ruxolitinib in patients with persistent or progressive myelofibrosis resulted in durable SVR35, improved TSS, hemoglobin response, and BMF. Further investigation is underway to qualify the potential for disease modification.
引用
- Harrison CN, Garcia JS, Somervaille TCP, et al. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol. 2022. PMID: 35180010. doi:10.1200/JCO.21.02188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。